Cargando…

Prostate Cancer Tumor Volume and Genomic Risk

BACKGROUND: Despite the historic association of higher prostate cancer volume with worse oncologic outcomes, little is known about the impact of tumor volume on cancer biology. OBJECTIVE: To characterize the relationship between tumor volume (measured by percent positive cores [PPC]) and cancer biol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramaswamy, Ashwin, Proudfoot, James A., Ross, Ashley E., Davicioni, Elai, Schaeffer, Edward M., Hu, Jim C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Prostate Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895765/ https://www.ncbi.nlm.nih.gov/pubmed/36743402 http://dx.doi.org/10.1016/j.euros.2022.12.002

Ejemplares similares

Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
por: Kensler, Kevin H., et al.
Publicado: (2022)

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes
por: Ben-Salem, Salma, et al.
Publicado: (2020)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
por: Kelly, Brian D., et al.
Publicado: (2023)

Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis
por: Basourakos, Spyridon P., et al.
Publicado: (2022)

Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study
por: Tosoian, Jeffrey J., et al.
Publicado: (2021)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

Partial-gland Cryoablation Outcomes for Localized Prostate Cancer in Patients with Magnetic Resonance Imaging (MRI)-visible and MRI-invisible Lesions
por: Zhu, Alec, et al.
Publicado: (2023)

Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis
por: Ntala, Chara, et al.
Publicado: (2021)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Reliability of Ancestry-specific Prostate Cancer Genetic Risk Score in Four Racial and Ethnic Populations
por: Shi, Zhuqing, et al.
Publicado: (2022)

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2022)

Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital
por: Kan, Carolyn K., et al.
Publicado: (2017)

Impact of Health-related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice in Low- and Intermediate-Risk Prostate Cancer
por: Riskin-Jones, Hannah, et al.
Publicado: (2020)

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects
por: Koitsalu, Marie, et al.
Publicado: (2021)

Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens
por: Aas, Kirsti, et al.
Publicado: (2021)

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
por: Sumanasuriya, Semini, et al.
Publicado: (2021)

Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
por: Press, Benjamin H., et al.
Publicado: (2022)

Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre
por: Nathan, Arjun, et al.
Publicado: (2021)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)
por: Woo, Henry H., et al.
Publicado: (2022)

Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol
por: Thankapannair, Vineetha, et al.
Publicado: (2023)

Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score–matching Study
por: Wei, Yongbao, et al.
Publicado: (2022)

Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
por: Olivier, Jonathan, et al.
Publicado: (2022)

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
por: Guldvik, Ingrid J., et al.
Publicado: (2020)

Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)

Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2022)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients
por: Laufer, Menachem, et al.
Publicado: (2023)

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
por: Remmers, Sebastiaan, et al.
Publicado: (2022)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f277el1jo0ubit1dvskb5etu84